To further enhance TME-dependent CD40 activation while minimizing systemic toxicity, a first-in-class mesothelin–CD40 bispecific antibody was recently engineered and tested in patients with tumors expressing high levels of mesothelin, such as PM and ovarian cancer. This evidence concerns the gene CD40 and ovarian cancer.